Reply from the Authors  by Stokes, Michael B. et al.
1716 Letters to the Editor
2. CARIDI G, BERTELLI R, DI DUCA M, et al: Broadening the spectrum
of diseases related to podocin mutations. J Am Soc Nephrol 14:1278–
1286, 2003
3. RUF RG, LICHTENBERGER A, KARLE SM, et al: Patients with mutations
in NPHS2 (podocin) do not respond to standard steroid treatment
of nephrotic syndrome. J Am Soc Nephrol 15:722–732, 2004
4. CARRARO M, CARIDI G, BRUSCHI M, et al: Serum glomerular per-
meability activity in patients with podocin mutations (NPHS2) and
steroid-resistant nephrotic syndrome. J Am Soc Nephrol 13:1946–
1952, 2002
Different meanings of
“glomerular tip lesion”
To the Editor: The term “glomerular tip lesion” [1] has
been used with three meanings:
(1) Our original description was in nephrotic patients
with structural changes at the tubular origin in glomeruli
that were otherwise normal. The clinical course resem-
bled that of minimal change nephropathy [2].
(2) We later realized that such changes were a com-
mon finding in many disorders, such as membranous
nephropathy [3]. These tip changes were not themselves a
disease, but could only be interpreted by consideration of
the rest of the glomerulus. Others have applied the term
“glomerular tip lesion” to these changes, irrespective of
the associated condition.
(3) We also reported tip changes in glomeruli show-
ing mesangial hypercellularity in the nephrotic syndrome,
sometimes with clinical progression [3, 4]. The ones who
did badly developed segmental sclerosis, corresponding
to many descriptions of “focal segmental glomeruloscle-
rosis.” We called the early stage early classical focal seg-
mental glomerulosclerosis [4].
‘Glomerular tip lesion,’ as defined by D’Agati et al [1],
also called “the tip variant of focal segmental glomeru-
losclerosis,” clearly includes our original definition, and
excludes tip changes in conditions such as membranous
nephropathy. Their definition allows mesangial hypercel-
lularity, and some of their patients may correspond to
early classical focal segmental glomerulosclerosis. Differ-
entiation between normal mesangium and mild mesan-
gial hypercellularity is arbitrary, but at the moment there
is no other satisfactory test to identify those who may
progress.
We agree with D’Agati et al that most patients with the
“glomerular tip lesion” by their definition, have steroid
responsive nephrotic syndrome and a good prognosis.
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Reply from the Authors
We agree with Dr. Howie that glomerular tip lesion
(GTL) may occur as a primary form in patients with idio-
pathic nephrotic syndrome, or may develop secondarily
in association with heavy proteinuria in diverse glomeru-
lar diseases [1]. We limited our study to primary GTL [2].
In our series, mesangial hypercellularity did not predict
outcome, defined as remission status at last follow-up.
None of our cases of primary GTL showed more than
mild mesangial hypercellularity, which was detected in
47% of GTL biopsies. Notably, the single GTL case that
progressed to end-stage renal disease lacked mesangial
hypercellularity.
Dr. Howie has observed that those cases with “struc-
tural changes at the tubular origin in glomeruli that were
otherwise normal” had a “clinical course resembling that
of minimal change disease.” Our data have shown, for
the first time, that routinely processed renal biopsies with
GTL frequently contained glomeruli with segmental le-
sions at other sites (peripheral or indeterminate, but not
perihilar), and most of these cases similarly followed a be-
nign course. Importantly, the segmental lesions were pre-
dominantly cellular (81%), rather than sclerosing. There
was no significant difference in remission status when
cases with GTL alone (26% of cases) were compared with
cases of GTL with segmental lesions at other glomerular
locations. Remission rate for GTL was better than for
idiopathic focal segmental sclerosis controls, but not as
good as that reported for adult minimal change disease.
For these reasons, we envision GTL as occupying an in-
termediate position, morphologically and clinically, in the
minimal change disease/focal segmental glomeruloscle-
rosis spectrum [3].
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How can we be sure that renal
dysfunction after coronary
angiography is just explained
by contrast nephropathy?
To the Editor: A review has been performed on the
very hot topic of the role of N-acetylcysteine (NAC) on
contrast nephropathy (CN) [1], of great clinical impact as
a result of the CN-linked role in worsening prognosis and
increasing costs. The authors wrote that they “assess the
efficacy of NAC for preventing CN after . . . intravenous
contrast media,” and concluded that “NAC may reduce
the incidence of increased creatinine after administration
of intravenous contrast, but this was of borderline statis-
tical significance.” However, both sentences are wrong
and misleading, as are similar conclusions reached by
another meta-analysis [2], because all 15 [1] or 16 [2]
reviewed papers regarded coronary angiography (CA),
except one [3]. First of all, to perform CA, contrast me-
dia are introduced into the arterial vascular bed, and
not intravenously, as when performing computed to-
mography (CT). Second, mechanisms of renal dysfunc-
tion after CA are not only caused by CN, but also by
other causes such as, for instance, cholesterol crystal
embolization.
We suggest that: (1) further studies be analyzed by
separating prevention strategies for CT from those for
CA; (2) for CA, attempts will be made to dissect other
causes of renal damage by looking for the blue toes
syndrome or eosinophilia, in order to exclude choles-
terol embolization; (3) even urea increase was consid-
ered as end point, to avoid the possibility that creatinine
changes might be resulting simply from a direct effect of
NAC [4].
The only quoted paper regarding the use of NAC be-
fore performing CT did demonstrate a protection, by also
using urea values as end point [3].
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We thank Dr. Canavese et al for their letter. We
agree that the term “intravenous contrast administra-
tion” may have been misleading. Perhaps the term
“parenteral contrast administration” would have been
preferable.
As we mentioned in our article, atheroemboli might
explain why NAC seemed to be less efficacious than
computed tomography in the context of coronary
angiography. For this reason we performed subgroup
analysis including only trials of patients undergoing coro-
nary angiography. Although “looking for blue toes or
eosinophilia” has theoretical appeal, we are uncertain
how helpful this would be, because such findings may
take weeks to appear [1], and clinically silent cholesterol
embolization after invasive procedures appears to be
common [2].
The suggestion to use serum urea rather than creati-
nine as an outcome measure seems to miss one of the
main points of our article—that data on costs or clini-
cally relevant outcomes such as death or hospitalization
(and not surrogates such as estimated kidney function)
are needed.
After reading their letter carefully, we are uncertain
whether Dr. Canavese et al feel that our conclusions are
